Physician profile
David W Backstedt
NPI 1245587203
$16,023.26
in general payments reported to CMS, 2019-2025
36 companies · $3,431 in 2025
The $3,431 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,278 · 2020: $927 · 2021: $2,064 · 2022: $2,352 · 2023: $2,926 · 2024: $3,046 · 2025: $3,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,178 · Education: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,178.42 |
| Education | $224.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,516.65 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Janssen Biotech, INC. | $2,347.90 | 2020-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $1,308.06 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $1,001.18 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $783.12 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Celgene Corporation | $537.84 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $464.42 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $421.61 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $408.07 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $336.25 | 2019-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $210.69 | 2020-2023 | |
| Janssen Scientific Affairs, LLC | $189.52 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $146.57 | 2019-2025 | |
| Amgen INC. | $135.81 | 2021-2023 | Avsola, Amjevita |
| Ironwood Pharmaceuticals, INC | $124.98 | 2021-2024 | Linzess |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $118.10 | 2024-2025 | Omvoh |
| Medtronic, INC. | $102.18 | 2025 | Interstim |
| Phathom Pharmaceuticals, INC. | $92.63 | 2024-2025 | Voquezna |
| Organon LLC | $73.78 | 2021-2023 | Renflexis |
| Madrigal Pharmaceuticals | $73.73 | 2025 | Rezdiffra |
| Next Science LLC | $73.67 | 2025 | Blastx, Xperience |
| Qol Medical, LLC | $68.66 | 2021-2022 | |
| Genzyme Corporation | $57.75 | 2023-2024 | |
| Ferring Pharmaceuticals INC. | $56.46 | 2019-2023 | Rebyota |
| Ardelyx, INC. | $55.78 | 2023-2024 | Ibsrela |
| Ucb, INC. | $52.40 | 2019-2020 | |
| Braintree Laboratories, INC. | $50.05 | 2019-2023 | Sutab, Suflave |
| Evoke Pharma, INC. | $48.33 | 2021-2023 | Gimoti |
| Micro-Tech Endoscopy USA, INC. | $44.63 | 2025 | Riteclip |
| Allergan, INC. | $39.51 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $23.30 | 2025 | Iqirvo |
| Celltrion USA INC. | $16.61 | 2025 | Vegzelma |
| Novo Nordisk INC | $16.29 | 2025 | Wegovy |
| Medtronic USA, INC. | $15.38 | 2020 | |
| Echosens North America, INC. | $11.35 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$38,544.56 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Backstedt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.